The French pharmaceutical Valneva’s vaccine is still under development and is one step closer to being authorized. Till the date, the european commission has approved four solutions against COVID-19: Pfizer / BioNTech, Moderna, AstraZeneca and Janssen unit dose; while the doses of CureVac, Novavax and Sanofi-GSK are still under continuous review by the European Medicines Agency (EMA).
Valneva is on the right track: he has announced that your vaccine produces a greater immune response than AstraZeneca. The French pharmaceutical company has carried out a study with about 4,000 participants divided into two groups. One of them was given AstraZeneca, and the other, the Valneva vaccine, which it is also given in two doses.
In addition to increased immunization, those who received Valneva recorded a fewer side effects and a good answer from the goal T, very important to eliminate COVID-19 from patients. Now, the French company is preparing new tests, one of them in people between 5 and 12 years of age.
Valneva increases 45% in the Stock Market
Due to the good results, Valneva plans request authorization from the European Union and the United Kingdom to administer its vaccine in both territories. In addition, the pharmaceutical has risen in Bag a 45% due to the positive outcome of his latest study.
The vaccine has a “more traditional approach to vaccine production than those used so far in the UK, Europe and North America and these results indicate that this new vaccine candidate is on track to perform. an important role in overcoming the pandemic“concludes Adam Finn, the trial’s principal investigator.
–
